PF-07329640 + sasanlimab

**PF-07329640 + sasanlimab** is a combination therapy under investigation for advanced solid tumors, including non-small cell lung cancer (NSCLC), colorectal cancer, urothelial cancer, and melanoma[5]. PF-07329640 is an experimental monoclonal antibody that targets the lymphotoxin beta receptor (LTβR), which plays a key role in immune regulation and tumor microenvironment modulation. Sasanlimab is a humanized immunoglobulin G4 (IgG4) monoclonal antibody that blocks programmed cell death protein 1 (PD-1), an immune checkpoint involved in downregulating immune responses[3]. When administered together, the intent is to leverage dual immune modulation—potentially enhancing antitumor activity by both sculpting the tumor microenvironment and blocking immune checkpoints. This combination is in early phase clinical trials to determine safety, efficacy, and optimal dosing[5].